Introduction: chemotherapy plus 1 year trastuzumab is the standard adjuvant treatment for HER2+ breast cancer patients (pts). The Short-HER study is an independent, non-profit study aimed to test the non-inferiority of 9 weeks vs 1 year of adjuvant trastuzumab. Methods: HER2+ breast cancer pts were randomized to: Arm A (Long) AC or ECx4 followed by 4 courses of 3-weekly docetaxel in combination with trastuzumab, followed by 14 additional courses of 3-weekly trastuzumab; or Arm B (Short) 3 courses of 3-weekly docetaxel plus weekly trastuzumab for 9 doses followed by FEC x3. When indicated, radiation therapy and hormone therapy were started after the completion of chemotherapy. ShortHER is a non-inferiority trial with disease-free survival (DFS) as primary end-point. The sample size of 1250 pts has been estimated on the basis of an hazard ratio <1.29 for the short arm to be non-inferior. The definitive analysis was planned after 198 DFS events or a 5yr median follow up. Hazard ratio for DFS and OS (90% CI) are estimated according to the Cox model; data are also analyzed by the Bayesian approach. Results: from Dec-2007 to Oct-2013, 1254 pts from 82 centers have been randomized. Pts characteristics are: median age 55 yrs (25-78); pts older than 60 yr 36%; stage I 40.6%, II 43.8%, stage III 15.2%; N0 53.5%, 1-3 positive nodes 30.7%, ≥ 4 15.2%. Sixty-eight% of the pts had ER+ tumors. Characteristics were balanced between the two arms. At the time of the analysis, 189 events have occurred and the median follow up of the study is 5.2 yrs. A total of 109 Grade ≥ 2 cardiac events have been reported, 82 in arm A (long) and 27 in arm B (short) (p < 0.0001); grade 3-4 cardiac events were 13 in arm A and 5 in arm B. Conclusions: Shorter trastuzumab administration significantly reduces the rate of severe cardiac toxicity. Final DFS data will be reported at the time of the meeting. EudraCT: 2007-004326-25.

3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer / Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 28:Issue suppl_6(2017).

3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

P Conte;A Frassoldati;F Piacentini;S Balduzzi;R D'Amico;V Guarneri
2017

Abstract

Introduction: chemotherapy plus 1 year trastuzumab is the standard adjuvant treatment for HER2+ breast cancer patients (pts). The Short-HER study is an independent, non-profit study aimed to test the non-inferiority of 9 weeks vs 1 year of adjuvant trastuzumab. Methods: HER2+ breast cancer pts were randomized to: Arm A (Long) AC or ECx4 followed by 4 courses of 3-weekly docetaxel in combination with trastuzumab, followed by 14 additional courses of 3-weekly trastuzumab; or Arm B (Short) 3 courses of 3-weekly docetaxel plus weekly trastuzumab for 9 doses followed by FEC x3. When indicated, radiation therapy and hormone therapy were started after the completion of chemotherapy. ShortHER is a non-inferiority trial with disease-free survival (DFS) as primary end-point. The sample size of 1250 pts has been estimated on the basis of an hazard ratio <1.29 for the short arm to be non-inferior. The definitive analysis was planned after 198 DFS events or a 5yr median follow up. Hazard ratio for DFS and OS (90% CI) are estimated according to the Cox model; data are also analyzed by the Bayesian approach. Results: from Dec-2007 to Oct-2013, 1254 pts from 82 centers have been randomized. Pts characteristics are: median age 55 yrs (25-78); pts older than 60 yr 36%; stage I 40.6%, II 43.8%, stage III 15.2%; N0 53.5%, 1-3 positive nodes 30.7%, ≥ 4 15.2%. Sixty-eight% of the pts had ER+ tumors. Characteristics were balanced between the two arms. At the time of the analysis, 189 events have occurred and the median follow up of the study is 5.2 yrs. A total of 109 Grade ≥ 2 cardiac events have been reported, 82 in arm A (long) and 27 in arm B (short) (p < 0.0001); grade 3-4 cardiac events were 13 in arm A and 5 in arm B. Conclusions: Shorter trastuzumab administration significantly reduces the rate of severe cardiac toxicity. Final DFS data will be reported at the time of the meeting. EudraCT: 2007-004326-25.
2017
28
Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turle...espandi
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer / Conte, P; Bisagni, G; Frassoldati, A; Brandes, A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Musolino, A; Garrone, O; Donadio, M; Cavazzini, G; Turletti, A; Zamagni, C; Danese, S; Ferro, A; Piacentini, F; Balduzzi, S; D'Amico, R; Guarneri, V. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 28:Issue suppl_6(2017).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1153023
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact